The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
Coronary revascularization interventions such as coronary artery bypass graft (CABG) and
percutaneous coronary intervention (PCI) are the standard of surgical treatment of patients
with myocardial ischemia. However, up to 30% of patients experience complications of varying
degrees within 12 months after the revascularization, or need for second intervention. Thus,
it is necessary to search for additional approaches to the postoperative treatment of
patients in order to improve the long-term results of revascularization treatment. Substances
of natural origin with an anti-atherosclerotic effect have a good potential. These
substances, as dietary supplements, can be taken by patients for a long time in conjunction
with other prescribed medicines and treatments. Another valuable direction of investigations
is the search for predictors of long-term cardiovascular complications after
revascularization, which can be markers of inflammation and heteroplasmy levels of the
patient's mitochondrial genome.
The purpose of this study is to determine whether the intake of dietary supplement Allicor at
a daily dose of 300 mg affects the frequency of long-term postoperative cardiovascular
complications and re-intervention in patients after revascularization operations on the
coronary arteries. The second goal is assessing the relationship between the grade monocytes
inflammatory response and the level of heteroplasmy of the mitochondrial genome of blood
leukocytes with the frequency of cardiovascular complications and re-interventions.